Drug Marketing in Tropical Regions and Its Effect on Pharmacovigilance Awareness and Reporting

Year : 2026 | Volume : 03 | Issue : 02 | Page : 1 17
    By

    Suraj Sen,

  • Anit Jha,

  • Rajeev Ratan,

  • Aman,

  • Ashish Pal,

  1. Principal, Dept. of Pharmacy, Harishchandra Pharmacy College, Jaunpur , U.P., India
  2. Academic Head, Dept. of Pharmacy, Harishchandra Pharmacy College, Jaunpur , U.P., India
  3. Assistant Professor, Dept. of Pharmacy, Harishchandra Pharmacy College, Jaunpur , U.P., India
  4. Scholar, Dept. of Pharmacy, Harishchandra Pharmacy College, Jaunpur , U.P., India
  5. Scholar, Dept. of Pharmacy, Harishchandra Pharmacy College, Jaunpur , U.P., India

Abstract

Drug marketing practices in tropical regions present a complex interplay between pharmaceutical promotion, healthcare infrastructure limitations, and public health outcomes. These regions – characterized by high disease burden, socio-economic disparities, and diverse healthcare delivery systems – often experience unique challenges in ensuring safe and rational drug use. Aggressive and sometimes unregulated marketing strategies by pharmaceutical companies may significantly influence prescribing behavior, patient compliance, and, ultimately, pharmacovigilance systems. Pharmacovigilance, defined as the science and activities related to the detection, assessment, understanding, and prevention of adverse drug reactions (ADRs), is crucial for ensuring drug safety post-marketing. However, in tropical regions, pharmacovigilance awareness and reporting remain suboptimal due to factors such as inadequate training, poor regulatory enforcement, lack of infrastructure, and limited public awareness. This review critically examines the influence of drug marketing strategies on pharmacovigilance awareness and ADR reporting in tropical regions. It explores marketing techniques employed, their impact on healthcare professionals and patients, and the systemic barriers that hinder effective pharmacovigilance practices. Additionally, it highlights the need for ethical marketing, regulatory strengthening, and capacity building to enhance drug safety monitoring. The article aims to provide a structured understanding of how marketing practices shape pharmacovigilance outcomes and suggests strategies to bridge gaps in awareness and reporting systems in tropical healthcare settings.

Keywords: Drug marketing, tropical regions, pharmacovigilance, adverse drug reactions, ADR reporting, pharmaceutical promotion, healthcare systems, drug safety, public health, regulatory affairs

[This article belongs to International Journal of Tropical Medicines ]

How to cite this article:
Suraj Sen, Anit Jha, Rajeev Ratan, Aman, Ashish Pal. Drug Marketing in Tropical Regions and Its Effect on Pharmacovigilance Awareness and Reporting. International Journal of Tropical Medicines. 2026; 03(02):1-17.
How to cite this URL:
Suraj Sen, Anit Jha, Rajeev Ratan, Aman, Ashish Pal. Drug Marketing in Tropical Regions and Its Effect on Pharmacovigilance Awareness and Reporting. International Journal of Tropical Medicines. 2026; 03(02):1-17. Available from: https://journals.stmjournals.com/ijtm/article=2026/view=244446


References

• World Health Organization. WHO guidelines on safety monitoring of herbal medicines in
pharmacovigilance systems. Geneva: World Health Organization; 2004.
• Geneva WH. The importance of pharmacovigilance: Safety monitoring of medicinal products.
Technical Report Series; 2002.
• Mugada V, Suryadevara V, Cheekurumilli M, Yarguntla SR. Signal detection in pharmacovigilance:
Methods, tools, and workflows from case identification to adverse drug reaction database entry. Przegl
Epidemiol. 2025;79(3):404–14.
• Guideline IH. Pharmacovigilance planning E2E. Curr Step. 2004;4.
• Sahu M, Nandave M, Kumar A. Pharmacovigilance system in India. In: Pharmacovigilance Essentials:
Advances, Challenges and Global Perspectives. Singapore: Springer Nature Singapore; 2024. p.147–62.
• Agarwal DS, Chairman DT. Central Drugs Standard Control Organization. New Delhi; 2017.
• Munshi RH, Singh KR, Thakkar AD. Understanding the degree of awareness among medical
professionals regarding the ethics of pharmaceutical marketing activities in context of revised
medical council of India code of ethics. Int J Basic Clin Pharmacol. 2016;5(2):263.
• Vogler M, Ricci Conesa H, de Araújo Ferreira K, Moreira Cruz F, Simioni Gasparotto F, Fleck K,
et al. Electronic reporting systems in pharmacovigilance: The implementation of VigiFlow in
Brazil. Pharm Med. 2020;34(5):327–34.
• Chibueze CN. The National Agency for Food and Drug Administration and Control (NAFDAC)
and the health ecosystem in Nigeria since the COVID-19 pandemic era. In: Nigerian History and
Development. p.227.
• Ho CM. A dangerous concoction: Pharmaceutical marketing, cognitive biases, and first amendment
overprotection. Ind Law J. 2019;94:773.
• Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, et al. Information
from pharmaceutical companies and the quality, quantity, and cost of physicians’ prescribing: A
systematic review. PLoS Med. 2010;7(10):e1000352.
• Oshikoya KA, Awobusuyi JO. Perceptions of doctors to adverse drug reaction reporting in a
teaching hospital in Lagos, Nigeria. BMC Clin Pharmacol. 2009;9(1):14.
• Gupta P, Udupa A. Adverse drug reaction reporting and pharmacovigilance: Knowledge, attitudes
and perceptions amongst resident doctors. J Pharm Sci Res. 2011;3(2):1064.
• Fadare JO, Enwere OO, Afolabi AO, Chedi BA, Musa A. Knowledge, attitude and practice of
adverse drug reaction reporting among healthcare workers in a tertiary centre in Northern Nigeria.
• Bhagavathula AS, Elnour AA, Jamshed SQ, Shehab A. Health professionals’ knowledge, attitudes
and practices about pharmacovigilance in India: A systematic review and meta-analysis. PLoS One.
2016;11(3):e0152221.
• Ofori-Asenso R, Agyeman AA. Irrational use of medicines—A summary of key concepts.
Pharmacy (Basel). 2016;4(4):35.
• Prasad P, Bajracharya SR, Deo S, Lamichhane S, Pradhan PM, Ghimire R, et al. Adherence of drug
promotional literatures distributed by pharmaceutical companies to World Health Organization
ethical criteria for medicinal drug promotion.
• Gagnon MA, Lexchin J. The cost of pushing pills: A new estimate of pharmaceutical promotion
expenditures in the United States. PLoS Med. 2008;5(1):e1.
• Hazell L, Shakir SA. Under-reporting of adverse drug reactions. Drug Saf. 2006;29(5):385–96.

Regular Issue Subscription Review Article
Volume 03
Issue 02
Received 04/05/2026
Accepted 07/05/2026
Published 20/05/2026
Publication Time 16 Days
11

Login


My IP

PlumX Metrics